Lead
A child's cheeks turn bright red. The pediatrician says: "Fifth disease." When you ask whether the child can return to school, the answer is: "Once the rash is out, there's essentially no longer any infectious period."
This reversal — "the rash appearing marks the end of contagiousness" — is the most important fact about fifth disease. It is the opposite of how most childhood infections work. But the same virus that makes this diagnosis reassuring for healthy children can pose a specific and real risk if it reaches a pregnant person in the same household. The school attendance question is almost beside the point. The priority question is: is there a pregnant person in this household, and do they know?
The Parvovirus B19 Timeline
Fifth disease is caused by human parvovirus B19: a common human virus that infects red blood cell precursors; it causes fifth disease in children and can pose serious risks to fetuses and immunocompromised individuals. Following infection, there is a period of approximately one week in which the virus is replicating in the bloodstream — the "viremic phase: the stage of infection when a virus is actively circulating in the bloodstream and transmission is at its peak" — during which infectious transmission is highest [1]. The rash appears after the viremia has resolved, as a product of the immune response (circulating antigen-antibody complexes) rather than active viral replication [1].
In concrete terms: the child who now has a visible rash has already cleared the most contagious phase. The week before the rash appeared — when the child went to school feeling only slightly off — was the period during which transmission was most likely occurring.
Under Japan's School Health and Safety Act, erythema infectiosum is not classified as a condition requiring mandatory school exclusion. Since infectious period coincides with the pre-rash phase rather than the visible rash, children who feel well may generally return to school [5]. Excessive isolation at this stage is not necessary.
In Adults: Joints, Not Cheeks
In healthy children, the classic presentation is the bright red "slapped cheek" rash followed by a lacy rash on the limbs. In adults, the presentation is often quite different: joint pain and arthritis tend to predominate, and there may be no rash at all [1]. "I thought it was a cold, then my wrists and knees started aching" is a recognizable adult pattern.
An estimated 50–60% of adults have IgG antibodies to parvovirus B19, reflecting prior infection and conferring immunity. The remaining 40–50% of adults are seronegative — they have no immunity [2]. It is this seronegative group that carries risk of primary infection.
Risk to Pregnant People: Gestational Age Is the Key Variable
When parvovirus B19 infects a pregnant person, the virus can cross the placenta and reach the fetus. In the fetus, parvovirus B19 suppresses the proliferation of erythroid precursor cells: immature cells in the bone marrow that develop into red blood cells, highly vulnerable to parvovirus B19 infection, causing severe anemia — which can progress to hydrops fetalis: a life-threatening fetal condition of generalized fluid accumulation and cardiac failure, a rare complication of parvovirus B19 before 20 weeks gestation (generalized fetal edema and cardiac failure) [1].
The risk depends heavily on gestational age at the time of infection:
- Infection before 20 weeks gestation: risk of hydrops fetalis approximately 3%; risk of fetal loss also elevated [3]
- Infection after 20 weeks: risk falls to below 1%. By this point, erythropoiesis has shifted primarily to the bone marrow, reducing the proportion of vulnerable precursor cells [3]
Hydrops fetalis can be detected on ultrasound. When detected early enough, intrauterine transfusion — direct fetal transfusion — is a treatment option in some cases [4]. A seronegative pregnant person who has been exposed to parvovirus B19 should contact their obstetrician promptly so that antibody status can be confirmed and, if indicated, ultrasound monitoring arranged.
Immunocompromised Children: A Different Risk
In immunocompetent children, viremia resolves in one to two weeks. In children with impaired immune function — congenital immunodeficiency, HIV, or those receiving chemotherapy for hematologic malignancy — the viremia can persist, resulting in chronic parvovirus B19 infection [1]. In this setting, continuous suppression of red cell production can lead to pure red cell aplasia: a severe condition where the bone marrow stops producing red blood cells, causing persistent deep anemia, a severe form of chronic anemia. Treatment involves intravenous immunoglobulin.
If an immunocompromised child is in an environment where they may be exposed to parvovirus B19 circulation, discussing preventive strategies with their specialist is advisable.
Household Response When a Pregnant Person Is Present
When a child is diagnosed with fifth disease, the household should recognize that if a seronegative pregnant person lives there, exposure has almost certainly already occurred — in the week before the rash appeared. Separating the child from the pregnant person at the rash stage has little practical effect as a prevention measure.
What matters is the following:
- Contact the obstetrician at the same time the child is diagnosed: The question is whether the pregnant person has prior immunity (IgG antibodies to parvovirus B19). This can be checked with a blood test at the obstetric clinic [4]
- If seronegative status is confirmed: The obstetrician will typically arrange ultrasound monitoring with fetal wellbeing in mind
- If antibody-positive: The risk of re-infection is very low; elaborate isolation measures are not necessary
Actions like "send the child to a relative's house" or "have the pregnant person move to their parents' home" have little value as infection control when the rash has already appeared. A call to the obstetrician does.
Summary
Fifth disease is, for the vast majority of healthy children, a mild and self-limited illness. The practical reassurance is real: the visible rash phase is not the contagious phase, and school exclusion is generally not warranted.
The risk that does need to be acted on is narrow but specific: a pregnant person in the first half of pregnancy who has not had prior parvovirus B19 infection. For that person, fetal hydrops risk — approximately 3% before 20 weeks — is a concrete number, not an abstraction. The most useful action when a child is diagnosed is not thinking about school attendance; it is asking whether anyone in the household is pregnant, and if so, making sure they know and contact their obstetrician.
References
- Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586–597. doi:10.1056/NEJMra030840. PMID: 14762186.
- Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol. 2006;21(4):421–435. doi:10.1016/j.reprotox.2005.01.006. PMID: 16182532.
- Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105(2):174–178. doi:10.1111/j.1471-0528.1998.tb10048.x. PMID: 9501781.
- Crane J, Mundle W, Boucoiran I, et al. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2014;36(12):1107–1116. doi:10.1016/S1701-2163(15)30390-X. PMID: 25551459.
- National Institute of Infectious Diseases (Japan). Erythema infectiosum and parvovirus B19 infection. IASR. 2019;40:1–3. Available from: https://www.niid.go.jp
- American Academy of Pediatrics. Parvovirus B19 (Erythema infectiosum, Fifth disease). In: Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. Itasca: AAP; 2021:572–577.